Bruker Launches CellScape XR to Scale Spatial Proteomics for Clinical Use
Event summary
- Bruker launched CellScape XR, a next-generation spatial proteomics platform, on February 25, 2026.
- The platform addresses bottlenecks in translational research by enabling high-throughput, reproducible spatial proteomics.
- CellScape XR incorporates advances in optics, fluidics, and protocols to improve throughput and workflow flexibility.
- University Hospital Schleswig-Holstein (UKSH) has analyzed over 1,000 clinically annotated samples using the CellScape platform.
The big picture
Bruker's launch of CellScape XR underscores the increasing demand for scalable, quantitative spatial proteomics in clinical research. The platform's ability to handle large patient cohorts positions it as a key player in the shift from discovery research to translational and diagnostic applications. The collaboration with UKSH highlights the platform's potential to support the development of prognostic assays across multiple solid tumor indications.
What we're watching
- Clinical Translation
- How quickly Bruker can transition CellScape XR from research to clinical diagnostic applications.
- Market Adoption
- Whether the platform's throughput and reproducibility will drive adoption among large clinical cohorts.
- Competitive Positioning
- The pace at which Bruker can differentiate CellScape XR in the growing spatial proteomics market.
Related topics